Use of the tumor necrosis factor-blockers for Crohn's disease

Table 9 Therapeutic gain for adalimumab induction of response and remission (%)

Study	Assessment week	ADA1	ADA2	ADA3	PL	Therapeutic gain
Gain	Response (CDAI ↓≥ 100 pts)
	1	-	-	20	12	8
	2	-	-	37	18	19
	4	-	-	38	25	13
	Remission
	1	-	-	6	4	2
	2	-	-	21	6	15
	4	-	-	21	7	14
(Classic I)	Response (CDAI ↓≥ 100 pts)
	1	23	25	21	16	7-9-5
	2	31	37	31	15	16-22-16
	4	34	40	50	25	9-15-25
	Remission
	1	16	13	16	7	9-6-9
	2	14	20	24	14	0-6-10
	4	18	24	36	12	6-12-24
(Classic I)	Response (CDAI ↓≥ 70 pts)
	1	-	-	6	4	2
	2	-	-	21	6	15
	4	-	-	21	7	14
	Response
	1	37	40	32	24	13-16-8
	2	44	55	45	30	14-25-15
	4	54	59	59	37	17-22-22

¹40 mg at week 0, 20 mg at week 2;

²80 mg at week 0, 40 mg at week 2;

³160 mg at week 0, 80 mg at week 2. PL: Placebo; CDAI: Crohn’s disease activity index; ADA: Adalimumab.